Marianne T Sweetser Selected Research

Flushing

9/2012	Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.
9/2012	Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Marianne T Sweetser Research Topics

Disease

12	Amyloidosis 03/2024 - 01/2019
8	Polyneuropathies (Polyneuropathy) 03/2024 - 01/2018
5	Injection Site Reaction 07/2023 - 11/2020
5	Inborn Genetic Diseases (Disease, Hereditary) 01/2023 - 01/2021
5	Pain (Aches) 11/2022 - 03/2006
5	Multiple Sclerosis 02/2017 - 09/2012
5	Relapsing-Remitting Multiple Sclerosis 02/2017 - 09/2012
4	Body Weight (Weight, Body) 10/2023 - 01/2018
3	Hyperoxaluria (Oxaluria) 01/2023 - 01/2021
3	Primary hyperoxaluria type 1 01/2023 - 01/2021
3	Psoriasis (Pustulosis Palmaris et Plantaris) 07/2006 - 12/2005
2	Kidney Calculi (Kidney Stone) 03/2022 - 01/2021
2	Renal Insufficiency (Renal Failure) 03/2022 - 01/2021
2	Nephrocalcinosis 03/2022 - 01/2021
2	Nausea 01/2022 - 09/2012
2	Cardiomyopathies (Cardiomyopathy) 12/2020 - 01/2020
2	Transthyretin-Related Hereditary Amyloidosis 01/2019 - 01/2018
2	Flushing 09/2012 - 09/2012
2	Infections 03/2011 - 12/2005
1	Hepatic Porphyrias (Hepatic Porphyria) 12/2023
1	Spasm (Spasms) 10/2023
1	Arthralgia (Joint Pain) 10/2023
1	Hypertension (High Blood Pressure) 07/2023
1	Hyperhomocysteinemia 09/2022
1	Mental Disorders (Mental Disorder) 01/2022
1	Iron Overload 01/2022
1	Fatigue 01/2022
1	Porphyrias (Porphyria) 11/2020
1	Acute Intermittent Porphyria (Porphyria, Acute) 11/2020
1	Diabetic Neuropathies (Diabetic Neuropathy) 09/2020
1	Orthostatic Intolerance 03/2020
1	Disease Progression 01/2019
1	Diarrhea 09/2012
1	Abdominal Pain (Pain, Abdominal) 09/2012
1	Pneumonia (Pneumonitis) 03/2011
1	Rheumatoid Arthritis 03/2011
1	Neoplasms (Cancer) 12/2005

Drug/Important Bio-Agent (IBA)

12	Prealbumin (Transthyretin)IBA 03/2024 - 01/2019
10	patisiranIBA 03/2024 - 01/2018
5	givosiranIBA 12/2023 - 11/2020
5	Dimethyl FumarateIBA 02/2017 - 09/2012
4	Hemin (Panhematin)FDA Link 11/2022 - 11/2020
4	Acute Hepatic PorphyriaIBA 09/2022 - 11/2020
3	lumasiranIBA 01/2023 - 01/2021
3	OxalatesIBA 01/2023 - 01/2021
3	Alefacept (Amevive)FDA Link 07/2006 - 12/2005
2	Heme (Haem)IBA 09/2022 - 01/2022
2	PorphobilinogenIBA 01/2022 - 11/2020
2	revusiranIBA 12/2020 - 01/2020
2	Transaminases (Aminotransferases)IBA 11/2020 - 09/2012
2	Proteins (Proteins, Gene)FDA Link 01/2020 - 01/2020
2	Glatiramer Acetate (Copaxone)FDA Link 10/2013 - 09/2012
1	AngiotensinogenIBA 07/2023
1	Peptides (Polypeptides)IBA 07/2023
1	AngiotensinsIBA 07/2023
1	Gonadotropin-Releasing Hormone (GnRH)FDA Link 11/2022
1	HomocysteineIBA 09/2022
1	EnzymesIBA 01/2022
1	Aminolevulinic Acid (Levulan)FDA Link 01/2022
1	Opioid Analgesics (Opioids)IBA 01/2022
1	RNA (Ribonucleic Acid)IBA 01/2021
1	CreatinineIBA 11/2020
1	Methionine (L-Methionine)FDA Link 01/2020
1	Valine (L-Valine)FDA Link 01/2020
1	AntigensIBA 06/2014
1	Tetanus Toxoid (Vaccine, Tetanus)FDA Link 06/2014
1	Natalizumab (Tysabri)FDA Link 06/2014
1	keyhole-limpet hemocyanin (keyhole limpet hemocyanin)IBA 06/2014
1	GoldIBA 10/2013
1	InterferonsIBA 09/2012
1	Tumor Necrosis Factor InhibitorsIBA 03/2011
1	Methotrexate (Mexate)FDA LinkGeneric 03/2011
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 03/2011
1	Rituximab (Mabthera)FDA Link 03/2011
1	Adalimumab (Humira)FDA Link 03/2011
1	Etanercept (Enbrel)FDA Link 03/2011
1	AntibodiesIBA 12/2005

Therapy/Procedure

7	RNAi Therapeutics 03/2024 - 01/2018
3	Therapeutics 01/2019 - 12/2005
1	Intravenous Administration 11/2020
1	Phototherapy (Light Therapy) 07/2006